Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice

SETH TOMBLYN1,2, ALISON E.B. SPRINGS2, JOHN F. LANGENHEIM1,2 and WEN Y. CHEN1,2

1Department of Biological Sciences, Clemson University, Clemson, SC 29634; 2Oncology Research Institute, Greenville Hospital System, Greenville, SC 29605, USA

Received November 6, 2008; Accepted December 30, 2008

DOI: 10.3892/ijo_00000242

Abstract. Previously, prolactin receptor antagonist (G129R)-based fusion proteins were developed including G129R fusions with an angiogenesis inhibitor (endostatin), an immune system modulator (interleukin 2), and a modified truncated cytotoxin (PE38KDEL). Each fusion protein was designed to target the PRLR-positive cells via the G129R moiety and at the same time attack a hallmark common to cancer cells via the second moiety. In this study, we tested the efficacy of the three fusion proteins as a combination therapy in an aggressive but clinically relevant mouse tumor model. To test the feasibility and to optimize a treatment regimen, allografts of a mammary carcinoma cell line (McNeuA) derived from an MMTV-neu transgenic mouse were first used. Growth of the allografts was significantly retarded by regimens which combined all three fusion proteins. In addition, a significant increase in cytotoxic CD8+ T cells was observed within the tumors of the combination treated groups. After establishing the dosing regimen, two doses of cocktail treatment (low and high doses administered twice weekly) along with individual component controls were administered to female MMTV-neu transgenic mice after surgical removal of a naturally occurring tumor. The average tumor recurrence time was significantly delayed in both low and high combination treatment groups in comparison to the no treatment control group (34, 50 and 18 days, respectively). The total number of lung metastases was also significantly decreased in both combination treatment groups. In conclusion, using G129R-based fusion proteins to target mammary carcinomas and to tackle multiple hallmarks of cancer at the same time was an effective strategy for treating HER2-positive mammary cancer in this mouse tumor model.

Introduction

Hormones that are intimately involved in normal mammary gland development such as estrogens, epidermal growth factor (EGF) and prolactin (PRL) influence the initiation and/or progression of breast cancer. Hormonal imbalance is a major contributing factor for developing breast cancer. Studies have shown that PRL is expressed in the epithelium of human breast cancers and that PRL receptor (PRLR) levels are higher in a majority of benign and malignant mammary tumors than the surrounding normal tissue (1,2). In addition, PRL and PRLR appear to have a role in both hormone responsive and hormone-independent breast cancers (3-5). For example, PRL has been shown to interact synergistically with estrogen and progesterone to promote cancerous growth; the receptors for these ligands are often co-expressed in primary breast cancers (3). Furthermore, PRL is able to transactivate HER2 through the activation of PRLR (4,5). In accordance, anti-proliferative effects of tamoxifen (6) or trastuzumab (7) were enhanced when they were combined with a PRLR antagonist, G129R.

G129R was developed for anti-breast cancer by substituting Gly at position 129 of human (h) PRL with Arg as previously reported (6,8). It has been demonstrated that G129R dose-dependently inhibits human breast cancer cell proliferation (6); competitively blocks hPRL-induced Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription (STAT), Ras/Raf-1/MEK/mitogen-activated protein kinases (MAPKs), and phosphoinositide 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1 (PDK1)/Akt signal transduction; and up-regulates TGF-β and down-regulates bcl-2 which in turn lead to the arrest of cell cycle progression and in some circumstances the induction of apoptosis (9-11). In an effort to generate mammary tissue-targeting therapeutics, dual-functional fusion proteins were generated which combined G129R with an angiogenesis...
inhibitor, G129R-Endostatin (12); an immune system modulator, G129R-Interleukin 2 (IL2) (13); or a modified truncated cytotoxin, G129R-PE40KDEL (14). It was demonstrated that the G129R moieties of the fusion proteins retained the ability to bind to PRLR, thus directing the fusion proteins to PRLR rich mammary cells and competitively blocking hPRL-induced signal transduction (12-14). The second moiety of the fusion proteins have also been shown to retain proper function. G129R-Endostatin was as effective as endostatin alone at inhibiting tube formation and proliferation of HUVEC cells (12). G129R-IL2 was able to stimulate the proliferation of CTLL2 cells as effectively as IL2 (13). G129R-PE40KDEL showed specificity towards breast cancer cells expressing the PRLR, inhibited protein synthesis, and induced cell death (14). Finally, both G129R-Endostatin and G129R-IL2 fusion proteins as a monotherapy were able to slow tumor growth in mice (12,13).

In recent years, the focus on cancer therapy has shifted from traditional chemotherapy, which employs small molecules that target DNA synthesis and replication activities, to novel therapeutic agents, which target unique biomarkers of cancer cells. Therapeutics have been designed which exploit over-expressed receptors (such as HER2/neu), tumor oncogenes (such as Bcr-Abl), or proteins associated with tumor angiogenesis (such as VEGF/VEGFR) (15-17). Another shift in the therapeutic paradigm has been the use of a combination approach in the hope that each component in the combination therapy will target a different mechanism exploited by the cancer, thus maximizing the response. For example, the use of trastuzumab along with paclitaxel, cisplatin, or radiation has been shown to increase the survival rate by ≥50% (18). Iminatinib mesylate, a small molecule Bcr-Abl inhibitor, sensitizes cancer cells to radiation (19). The use of a monoclonal antibody specific for the EGFR receptor (EGFR), cetuximab, and a small molecular inhibitor of the EGFR, gefitinib, in combination show a shared complementary mode of action and a synergistic response in vivo (20,21).

In the present study, a clinically relevant mouse tumor model was used to test the efficacy of a combination therapy composed of three fusion proteins, G129R-IL2, G129R-Endostatin and G129R-PE40KDEL. A highly significant and dose-dependent delay in tumor recurrence and a reduction in lung metastases were observed in mice treated with the fusion protein combinations.

Materials and methods

Protein production. The pET22b(+) based plasmids containing cDNAs encoding G129R-PE40KDEL, G129R-IL2 or G129R-Endostatin were transformed into Rosetta (DE3)pLysS competent E. coli cells (Novagen/EMD Biosciences, San Diego, CA). Protein expression, isolation of inclusion bodies, refolding, and purification protocols were reported previously (6,12). The function of both moieties of each fusion protein was determined as described previously (12-14). To improve the yield of G129R-IL2, an unpaired Cys at position 125 of IL2 was substituted with an Ala. This substitution mutation does not affect the function of IL2 (22). To enhance the cytotoxicity of G129R-PE40KDEL, domain 1a of the toxin moiety was removed to create G129R-PE3aKDEL (23).

Transgenic mice. Breeding pairs of FVB/N-Tg(MMTVneu) 202Mul/J mice, homozygous for the unactivated form of rat erbB2/neu transgene under the control of the mouse mammary tumor promoter (MMTV-neu) (24) were obtained from Jackson Laboratory (Jackson Laboratory, Bar Harbor, Maine). The colony was expanded and housed in accordance with The Guide for the Care and Use of Laboratory Animals. To implant allografts or remove tumors, mice were anesthetized with 0.4 mg/g body weight of 2,2,2-tribromethanol (Sigma-Aldrich, St. Louis, MO) prepared in tert-amyl alcohol (Sigma-Aldrich) and saline.

RT-PCR. To confirm expression of mouse PRLR, mammary gland or tumor tissue of MMTV-neu transgenic mice were dissected and frozen until time of use. Approximately 50-100 mg of frozen tissue was homogenized in 1 ml TRizol (Invitrogen, Carlsbad, CA) on ice using a motorized homogenizer and processed according to the manufacturer’s instructions to isolate RNA. RT-PCR was performed with the Access Quick RT-PCR system (Promega, Madison, WI) using the following conditions: 45 min at 48˚C; 1 min at 94˚C; 25 cycles: 30 sec at 94˚C, 1 min at 62˚C, 1 min at 72˚C; 6 min at 72˚C; and a final hold at 4˚C. Primers used for mouse PRLR were 5'-GGCCCAATTTCTGTGTCTTACG-3' and 5'-GCCACTGCCGCCACATATACAAC-3'; primers for glyceraldehyde 3-phosphate dehydrogenase (G3PDH) were 5'-ACACGATCATGCCATACAC-3' and 5'-TCCACACCTGGTCTGTA-3'. To ensure no DNA contamination, separate reactions were run without the reverse transcriptase.

McNeuA allograft experiment. McNeuA cells were kindly provided by Dr Michael Campbell, and cultured as previously described (25). At time of implantation, cells were trypsinized, washed with growth medium, counted and re-suspended at a concentration of 3×10^6 cells/0.1 ml in PBS. The mixture was diluted 1:1 (v/v) with Matrigel (BD Biosciences, Franklin Lakes, NJ) and injected into the anterior fat pad of 3-month old homozygous MMTV-neu virgin female mouse (0.2 ml/mouse). Mice were randomly sorted into 9 groups of 4 mice and treatments with the fusion proteins were initiated three days after implantation.

Mice were intraperitoneally (i.p.) administered a low dose of each fusion protein individually (50 μg G129R-Endostatin, 50 μg G129R-IL2, or 10 μg G129R-PE3aKDEL), a high dose of each fusion protein individually (100 μg G129R-Endostatin, 100 μg G129R-IL2, or 25 μg G129R-PE3aKDEL), the combination of the low doses, the combination of the high doses, or PBS. All dosages were adjusted to a single 0.2 ml injection volume. Dosages were determined from previous published data. These dosages were non-lethal and showed ample difference in growth of T-47D xenografts in nude mice (12,13). Treatments were administered every three days for 27 days. The short (S) and long (L) axes of the tumors were measured and the tumor volume (V) was calculated using the formula for a spheroid (V = 4/3π x S/2 x S/2 x S/2). On day 28 of the experiment, tumors were dissected and split into thirds: one part for fixation in formalin, one part for flow cytometry and one part for cryopreservation. Spleens were removed for flow cytometry. Lungs were removed and stained in Bouin’s Fixative (Sigma-Aldrich). The presence or
absence of macrometastases was recorded and the \(\chi^2\) test of independence was used to determine significance between treatment groups.

**MMTV-neu transgenic mouse mammary tumor surgical model.** Due to natural variation in tumor formation rates, mammary tumors from 6 to 10 MMTV-neu mice were removed in intervals based upon similarity in tumor size. Healthy mice showing no ill effects from the surgery were randomized into control and treatment groups. The day after surgery, mice were started on a twice weekly low dose combination regimen (100 \(\mu\)g G129R-Endostatin, 100 \(\mu\)g G129R-IL2, and 20 \(\mu\)g G129R-PE38KDEL), high dose combination regimen (200 \(\mu\)g G129R-Endostatin, 200 \(\mu\)g G129R-IL2, and 25 \(\mu\)g G129R-PE38KDEL), 200 \(\mu\)g G129R 5 days per week, or PBS. Animals were palpitated at time of injections and tumor recurrence was noted; treatments were ceased after recurrent tumors reached ~1 cm in diameter at which point animals were sacrificed and handled as described above. Kaplan-Meier survival analysis was performed on tumor recurrence utilizing new tumor formation as the end-point. Log-rank analysis was performed to determine significance between individual comparisons and the overall experiment.

**Flow cytometry.** Single cell suspensions were obtained from the isolated spleens and allograft fractions. The re-suspended splenocytes were diluted 1:10 to 1:20 in Guava® ViaCount® Reagent (Guava Technologies, Hayward, CA) which contains two DNA-binding dyes, one of which selectively penetrates apoptotic and dead cells characterized by compromised membrane integrity, and one which penetrates all nucleated cells. Following the 5-min incubation, the stained cells were analyzed on a Guava Personal Cytometer (Guava Technologies). Each sample was analyzed using Guava CyoAnalysis software (Guava Technologies). The total cellular population was determined for each sample and results are reported as averages and SEM of each group. The single cell suspensions from the allografts were enriched for tumor-infiltrating lymphocytes by Percoll (Sigma-Aldrich) density gradient centrifugation. Tumor-infiltrating lymphocytes were collected at the 1.055-1.07 g/ml interface and washed three times with PBS. As per guidelines from Guava Technologies, cells were incubated with 5 \(\mu\)g/ml of antibodies directed against CD3 and CD4 or CD3 and CD8. All antibodies were obtained in conjugated form from BD Biosciences (San Jose, CA). Antibody/enzyme complex was visualized with DAB (Biocare Medical) or anti-CD31 (MEC13.3, Biocare Medical) for 60 and 45 min, respectively, and detected using the Evision+ Dual Link System-HRP detection kit (Dako, Carpinteria, CA). Antibody/enzyme complex was visualized with DAB (Biocare Medical) for 3 min and counterstained with hematoxylin for 5 min.

**Immunohistochemistry.** Formalin-fixed tumors were paraffin-embedded, cut into 5-\(\mu\)m sections and placed on glass slides. The sections were deparaffinized in xylene and rehydrated in a graded series of ethanol. The sections were deparaffinized in xylene and rehydrated in a graded series of ethanol. The sections were then covered by eosin for 60 sec, washed with water and dehydrated with ethanol. The slides were placed in xylene before securing a cover slip. For antigen retrieval, deparaffinized and rehydrated slides were submerged in high pH antigen retrieval solution (Biocare Medical, Concord, CA), placed under pressure in a decloaking chamber (Biocare Medical), and washed with distilled water. Slides were blocked for 10 min and incubated with anti-CD4 (BC/1F6, Biocare Medical) or anti-CD31 (MEC13.3, Biocare Medical) for 60 and 45 min, respectively, and detected using the Evision® Dual Link System-HRP detection kit (Dako, Carpinteria, CA). Antibody/enzyme complex was visualized with DAB (Biocare Medical) for 3 min and counterstained with hematoxylin for 5 min.

**Results**

**PRLR expression levels in normal or malignant mammary tissue of MMTV-neu mice.** PRLR expression levels in tumors and normal mammary gland of MMTV-neu mice were compared by RT-PCR. As shown in Fig. 1, expression levels of mouse PRLR in the tumors were significantly increased (P<0.05) as compared to that of adjacent normal mammary gland, providing a rationale for targeted treatment with the PRLR antagonist based fusion proteins. In data not shown, the reactions were run without reverse transcriptase to ensure that the product observed was not from DNA contamination.

**McNeuA allograft studies.** The tumor growth rate of all treatment groups was retarded by day 24 of the study as compared to that of the PBS controls (Fig. 2A, low dose; and Fig. 2B, high dose). As shown in Fig. 2A, a significant difference in the tumor volumes was observed for both G129R-PE38KDEL monotherapy and the combination (P<0.001 in both cases). While a decrease in tumor volume was observed in the G129R-IL2 and G129R-Endostatin treatment groups, these differences were not significant. In the high dose treatments groups there was also a significant
reduction in tumor volume in the G129R-PE38KDEL and combination treatment groups (P<0.001 in both cases). No significant difference in tumor volume was observed between the groups receiving low or high dose combination treatments.

To examine the IL2-like activity of G129R-IL2, as well as determine any signs of global toxicity, tumor infiltrating lymphocytes and splenic cellularity were examined by flow cytometry. In comparison to the PBS control group, a significant increase (P<0.05) in the percent of CD8+ cells (Fig. 3A) was observed within the tumors of the mice receiving the high-dose combination treatment. No significant difference was observed in cells labeled with anti-CD4 or anti-CD3 (data not shown). There was no significant alteration in the total cellularity within the spleens of either of the combination groups when compared to the PBS control groups (Fig. 3B). No alterations were observed in body weight, physical appearance, or behavior (data not shown).

MMTV-neu transgenic mouse mammary tumor surgical model studies. A novel and more clinically relevant mouse tumor model was developed for this study. Naturally occurring tumors were surgically removed from MMTV-neu mice. Surgery was followed with adjuvant treatment to thwart tumor recurrence. Based upon the results from McNeuA allograft study, two different combination regimens were used in the surgical tumor model study. After surgical removal of the primary tumor, the mice were treated with PBS, G129R, three individual fusion proteins as a monotherapy, or combination of the three G129R fusion proteins at low or high doses. Kaplan-Meier survival analysis was performed using tumor recurrence as the end-point (Fig. 4). The overall significance of the study, when all treatment groups were included, was found to be P<0.004.

The median values for tumor recurrence were doubled in...
for G129R-PE38KDEL was 40 days, G129R-IL2 31.5 days, and G129R-Endostatin 39 days. Each component was significantly different from both PBS and the high combination ("P<0.02). Log-rank analysis of the survival curve revealed a highly significant difference between the treated groups and the control (P<0.004). (C) Total lung metastasis. Lungs were excised at sacrifice and fixed in Bouin’s fixative to observe metastasis. The percentages of animals with lung metastases are reported and the \( \chi^2 \) test for independence determined that the high dose combination treatment group developed lung metastases only 40% of the time, compared to 78% for PBS (Fig. 4C). This reduction was also significantly lowered by G129R-PE38KDEL (30%). It is noteworthy that although there was no difference between the G129R treatment group (18 days) and the PBS control group (17 days) in median values for tumor recurrence (Fig. 4A), there was a significant reduction (33%) in lung metastases in the group receiving G129R treatment as compared to PBS control. All other individual treatments showed no significant reduction in lung metastases. The \( \chi^2 \) test for independence determined that the high combination, G129R, and G129R-Endostatin treated groups differed significantly from the PBS group and that the G129R-IL2 and G129R-Endostatin receiving groups differed from the high combination treated group. There was no appreciable difference between the age of mice at time of surgery and the mass of tumors removed nor were there any signs of toxicity, i.e., no alteration in body weight, appearance or behavior.

Specific biomarkers were examined in secondary tumor samples to analyze the specific efficacy of the fusion proteins. Since G129R-Endostatin fusion protein was designed to serve as a targeted angiogenesis inhibitor, the blood vessel density (measured by CD31 level, an endothelial cell marker) within the recurrent tumors was examined. An obvious decrease in CD31-positive cells was observed in all treatment groups when compared to the PBS group, suggesting a reduced vessel density within the tumors (Fig. 5A). There was no significant difference between the treatment groups. To examine response to the G129R-IL2 fusion protein, tumor sections were stained for CD4, a marker of T helper cells. There was a remarkable increase in the number of CD4-positive cells observed in the treatment groups when compared to the PBS control group (Fig. 5B).

Discussion

Conventional cancer treatment begins with radiation therapy or small molecules that target DNA synthesis and replication activities. Treatment is usually followed by surgical removal of the shrunken mass. After surgery, patients typically receive additional rounds of radiation and/or chemotherapy (26). While there have been vast improvements in the equipment for delivering radiation therapy (27) and new methods of administering the chemotherapy (28), these methods often damage many non-cancerous cells due to a lack in specificity, thereby resulting in significant adverse side-effects. In the past 10-15 years the paradigm of cancer chemotherapy has been shifted towards designing so-called ‘smart molecules’ that have ability to selectively target cancer cells. Efforts have aimed at identifying and targeting unique markers of cancer cells such as over-expressed receptors, tumor antigens, or unique biological features of a tumor (29). Therapeutics targeting breast cancer based on receptor status have yielded a wide array of options for treatment of the disease including selective estrogen receptor (ER) modulators (SERMs) for ER-positive cancers (30) and trastuzumab (16) or lapatinib (31) for HER2-positive cancers. Over-expression of PRLR in breast cancer led to the development of a PRLR antagonist, G129R, and G129R based fusion proteins (12-14).
Another important trend in cancer therapy has been to develop effective combinatorial approaches. Strategies for combining chemotherapies that have proven effective as a single agent fall into at least three categories. First of which is to use agents that attack the same oncoprotein via different mechanisms. For example, trastuzumab and lapatinib or trastuzumab and pertuzumab have been used to treat HER2-positive breast cancer (16) and cetuximab with gefitinib or erlotinib to treat EGFR-over-expressing tumors (15). A second approach to maximize the efficacy of combination therapy is to attack multiple targets present in same oncogenic signaling cascade. For example, the src homology domain has been shown to have a critical role in HER2 signaling and is believed to be an important factor for metastasis of HER2 over-expressing cancers (32). The use of dasatinib, a small molecule inhibitor of src has proven beneficial to HER2-positive breast cancer (33). Furthermore, use of trastuzumab in combination with the PRLR antagonist, G129R, has also been shown to have an additive inhibitory effect on HER2 and MAPK phosphorylation, and the proliferation of T-47D and BT-474 breast cancer cells both in vitro and in vivo (4). Finally, attacking multiple hallmarks of cancer simultaneously using various cancer therapeutics is under investigation. An example of this approach would be use of trastuzumab, which targets the oncogene HER2, in combination with bevacizumab, which targets tumor angiogenesis, which has been demonstrated effective in small cell lung cancer (17).

In this study, the efficacy of using three fusion proteins (G129R-IL2, G129R-PE38KDEL, G129R-Endostatin) to target breast cancer and multiple hallmarks of cancer was examined. The in vivo capabilities of two of these fusion proteins has been previously tested using breast cancer cell xenograft model (12,13). These results are further confirmed in this study (Fig. 2) utilizing the McNeuA mammary cancer cell line derived from an MMTV-neu mouse tumor (25). The McNeuA allograft study laid the foundation for optimization of fusion-protein dosages in our surgical model. The data presented here are also the first demonstration of the function of the second moiety of the fusion proteins in vivo. The T-cell infiltration in the allograft and surgical models (Figs. 3A and 5B) demonstrate the ability of peripherally administered G129R-IL2 to enhance the immune response to the tumor without causing serious systemic immune reaction, as evidenced by the lack of increased cellularity in the spleens (Fig. 3B). The decrease in blood vessel density within the tumors of the surgical model indicates (Fig. 5A) that G129R-Endostatin can limit angiogenesis in vivo.

Although models utilizing human cancer cells implanted into athymic mice have been widely used and proven to be a valuable tool in drug testing, these models have major drawbacks; in particular, they lack the host immune system
influence on the tumor. In addition, xenograft models do not characterize natural tumor developmental processes. Therefore, the surgical mouse tumor model presented here may prove to be more clinically relevant since it simulates a clinical setting, i.e., therapies applied after surgical removal of naturally occurring primary tumors. The efficacy of the therapy is not measured by slowing the growth of tumor but by the tumor recurrence time/rate and metastasis index.

The data presented here demonstrate that the G129R fusion proteins significantly delayed tumor recurrence (Fig. 4A and B), reduced lung metastasis (Fig. 4C), decreased the blood vessel density within the tumor (Fig. 5A), and increased the quantity of CD4+ cells within the recurrent tumors (Fig. 5B). There was a highly significant and dosage-dependent delay in tumor recurrence when comparing the PBS control to either combination group (Fig. 4A). If the life expectancy of a human female (34) is compared with that of the MMTV-neu mouse (35), an average of 17 days post-surgery tumor-free phase in the control group translates to approximately 3-5 years in a human. Remarkably, the low dose combination treatment resulted in a 2-fold increase in the tumor-free phase (34 days). The tumor recurrence rate in the high combination treated group was one-third of that of the control group.

Metastasis of the tumor to a distant site is typically the leading cause for the deterioration of the patient and ultimately determines the patient's ability to survive after surgical removal. In our study model, both the low and high dosages of the combination therapies yielded >50% reduction in total lung metastasis lesions, which directly translates to total survival time. The ability to measure distant metastasis further demonstrates the clinical relevance and utility for the novel surgical model presented herein. The difference observed in total lung metastases in response to the three fusion proteins as monotherapy (Fig. 4C) may be attributed to the function of the second moiety of each fusion protein. The cytotoxic nature of the G129R-PE38KDEL allows it to elicit its effect directly on tumor cells, while both G129R-IL2 and G129R-Endostatin were designed to target tumor hallmarks such as host immune system and tumor angiogenesis in addition to the tumor cells. Therefore, one can speculate that G129R-PE38KDEL is more effective at decreasing circulating PRLR-positive tumor cells, thereby reducing metastasis, and G129R-IL2 and G129R-Endostatin fusion is more effective on established tumors.

It is noteworthy that G129R monotherapy has minimal effect both in vitro (data not shown) and in the surgical model (Fig. 4A) measured by tumor recurrence as compared to the PBS control group. However, G129R was surprisingly effective at preventing lung metastasis in the surgical model (Fig. 4C). As a matter of fact, daily G129R treatment was as effective as the twice weekly high dose combination treatment, which further confirms the therapeutic potential of G129R in HER2-positive breast cancer.

In conclusion, this report presents a novel approach utilizing G129R-fusion proteins to specifically target multiple hallmarks of cancer. This combination therapy proved to be significantly effective at reducing tumor growth as well as tumor recurrence and metastasis. Further, this report presents a new method for the testing of therapeutic strategies in a clinically relevant setting.

Acknowledgements

The authors would like to thank Faye Bryson and Pathology Consultants of Greenville, SC for their time in preparing the materials for the labeling of the IHC(P) sections with CD4 and CD31. We would also like to thank Guillermo De Angulo for his assistance with the mouse surgeries and dosing. This work was supported in part by the Endowment Fund of the Greenville Hospital System and grants from the Susan G. Komen Foundation (BCTR0402985 and BCTR091306).

References


